Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.bbrc.2020.10.094 http://scihub22266oqcxt.onion/10.1016/j.bbrc.2020.10.094 33272566!7678433!33272566     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33272566&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Biochem+Biophys+Res+Commun 2021 ; 538 (?): 137-144 Nephropedia Template TP {{tp|p=33272566|t=2021. Identifying and repurposing antiviral drugs against severe acute respiratory syndrome coronavirus 2 with in silico and in vitro approaches |pdf=|usr=}}{{33272566}} gab.com Text Identifying and repurposing antiviral drugs against severe acute respiratory syndrome coronavirus 2 with in silico and in vitro approaches JO: Biochem Biophys Res Commun http://www.kidney.de/pget.php?&tw=1&pmid=33272566 #FOAvip Coronavirus infectious diseases 2019 (COVID-19), a global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been a serious public health threat worldwide. So far, there are no drugs and vaccines whose efficacy has been well-proven. After the outbreak, there has been a massive search for anti-SARS-CoV-2 medications, focusing on approved drugs because repurposing approved drugs will take less time to reach clinical usage than new drugs. This article summarizes the studies using in silico and in vitro approaches to identify therapeutic candidates among approved drugs that target the SARS-CoV-2 life cycle. Twit Text FOAVip Identifying and repurposing antiviral drugs against severe acute respiratory syndrome coronavirus 2 with in silico and in vitro approaches ????Biochem Biophys Res Commun http://www.kidney.de/pget.php?&tw=1&pmid=33272566 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33272566 #FOAvip English Wikipedia <ref>{{Cite pmid|33272566}}</ref> Identifying and repurposing antiviral drugs against severe acute respiratory syndrome coronavirus 2 with in silico and in vitro approaches #MMPMID33272566 Watashi K Biochem Biophys Res Commun 2021[Jan]; 538 (?): 137-144 PMID33272566show ga Coronavirus infectious diseases 2019 (COVID-19), a global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been a serious public health threat worldwide. So far, there are no drugs and vaccines whose efficacy has been well-proven. After the outbreak, there has been a massive search for anti-SARS-CoV-2 medications, focusing on approved drugs because repurposing approved drugs will take less time to reach clinical usage than new drugs. This article summarizes the studies using in silico and in vitro approaches to identify therapeutic candidates among approved drugs that target the SARS-CoV-2 life cycle. |*COVID-19 Drug Treatment[MESH] |Animals[MESH] |Antiviral Agents/*chemistry/pharmacology/therapeutic use[MESH] |Caco-2 Cells[MESH] |Chlorocebus aethiops[MESH] |Computer Simulation[MESH] |Drug Repositioning/*methods[MESH] |Humans[MESH] |Mice[MESH] |SARS-CoV-2/*drug effects[MESH]Identifying and repurposing antiviral drugs against severe acute respi(epmc).pdf DeepDyve Pubget Overpricing